Passage Bio Competitors

Passage Bio (NASDAQ:PASG) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Passage Bio and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Passage Bio and SpringWorks Therapeutics, as provided by MarketBeat.com.

Passage Bio currently has a consensus target price of $25.5297, indicating a potential upside of 31.39%. SpringWorks Therapeutics has a consensus target price of $91.00, indicating a potential upside of 31.31%. Given Passage Bio's higher probable upside, research analysts clearly believe Passage Bio is more favorable than SpringWorks Therapeutics.

Insider and Institutional Ownership

67.6% of Passage Bio shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Passage Bio and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Summary

Passage Bio beats SpringWorks Therapeutics on 4 of the 7 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares Revolution Medicines and Passage Bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Revolution Medicines and Passage Bio, as reported by MarketBeat.

Revolution Medicines currently has a consensus price target of $50.75, suggesting a potential upside of 19.55%. Passage Bio has a consensus price target of $25.5297, suggesting a potential upside of 31.39%. Given Passage Bio's higher probable upside, analysts clearly believe Passage Bio is more favorable than Revolution Medicines.

Institutional & Insider Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 67.6% of Passage Bio shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Revolution Medicines and Passage Bio's revenue, earnings per share (EPS) and valuation.

Passage Bio has lower revenue, but higher earnings than Revolution Medicines.

Summary

Passage Bio beats Revolution Medicines on 5 of the 8 factors compared between the two stocks.

Passage Bio (NASDAQ:PASG) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Passage Bio and NantKwest's gross revenue, earnings per share (EPS) and valuation.

Passage Bio has higher earnings, but lower revenue than NantKwest.

Profitability

This table compares Passage Bio and NantKwest's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Passage Bio and NantKwest, as reported by MarketBeat.

Passage Bio currently has a consensus price target of $25.5297, suggesting a potential upside of 31.39%. NantKwest has a consensus price target of $18.00, suggesting a potential downside of 30.10%. Given Passage Bio's higher possible upside, analysts clearly believe Passage Bio is more favorable than NantKwest.

Insider and Institutional Ownership

67.6% of Passage Bio shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Passage Bio beats NantKwest on 6 of the 9 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Profitability

This table compares Editas Medicine and Passage Bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Editas Medicine and Passage Bio, as provided by MarketBeat.com.

Editas Medicine currently has a consensus target price of $49.2222, suggesting a potential upside of 21.96%. Passage Bio has a consensus target price of $25.5297, suggesting a potential upside of 31.39%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Editas Medicine.

Institutional & Insider Ownership

87.5% of Editas Medicine shares are owned by institutional investors. Comparatively, 67.6% of Passage Bio shares are owned by institutional investors. 0.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Editas Medicine and Passage Bio's gross revenue, earnings per share (EPS) and valuation.

Passage Bio has lower revenue, but higher earnings than Editas Medicine.

Summary

Passage Bio beats Editas Medicine on 6 of the 9 factors compared between the two stocks.

NanoString Technologies (NASDAQ:NSTG) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

98.3% of NanoString Technologies shares are held by institutional investors. Comparatively, 67.6% of Passage Bio shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for NanoString Technologies and Passage Bio, as reported by MarketBeat.com.

NanoString Technologies currently has a consensus target price of $63.00, indicating a potential upside of 3.26%. Passage Bio has a consensus target price of $25.5297, indicating a potential upside of 31.39%. Given Passage Bio's higher probable upside, analysts plainly believe Passage Bio is more favorable than NanoString Technologies.

Valuation & Earnings

This table compares NanoString Technologies and Passage Bio's revenue, earnings per share (EPS) and valuation.

Passage Bio has lower revenue, but higher earnings than NanoString Technologies.

Profitability

This table compares NanoString Technologies and Passage Bio's net margins, return on equity and return on assets.

Summary

Passage Bio beats NanoString Technologies on 5 of the 9 factors compared between the two stocks.

Sorrento Therapeutics (NASDAQ:SRNE) and Passage Bio (NASDAQ:PASG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider and Institutional Ownership

27.4% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 67.6% of Passage Bio shares are owned by institutional investors. 3.4% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Sorrento Therapeutics and Passage Bio's gross revenue, earnings per share and valuation.

Passage Bio has lower revenue, but higher earnings than Sorrento Therapeutics.

Profitability

This table compares Sorrento Therapeutics and Passage Bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Sorrento Therapeutics and Passage Bio, as reported by MarketBeat.

Sorrento Therapeutics currently has a consensus price target of $28.75, indicating a potential upside of 226.33%. Passage Bio has a consensus price target of $25.5297, indicating a potential upside of 31.39%. Given Sorrento Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sorrento Therapeutics is more favorable than Passage Bio.

Summary

Passage Bio beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.